NEW YORK, March 13 – Canadian proteomics company Caprion Pharmaceuticals said Tuesday it had raised C$6.2 million ($4.1 million) in a secondary round of private financing managed by Yorkton Securities and led by Ventures West and Fidelity Management & Research.

Caprion of Montreal has raised a total of C$58.1 million to date, not including a C$11.6 million investment from Micromass for the application of Micromass' mass spectrometry technologies to Caprion's proteomics efforts.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.